Results 151 to 160 of about 201,604 (251)

Epstein-Barr Virus Infection at Single-Cell Resolution. [PDF]

J Med Virol
SoRelle ED.
europepmc   +1 more source

Acyclovir‐Resistant Herpes Simplex Virus in Pediatric Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant: A Case Series

Transplant Infectious Disease, EarlyView.
This retrospective case series of acyclovir‐resistant HSV infection in pediatric patients undergoing allogeneic HSCT discusses the clinical course, associated complications, and treatment, including side effects. We propose the first algorithm for investigating and managing acyclovir‐resistant HSV infections in pediatric HSCT recipients, highlighting ...
Jenna Nunn, Ahmed Ahmed, Srividhya Senthil, Oana Mirci‐Danicar, Denise Bonney, Claire Horgan, Omima Mustafa, Robert Wynn, Malcolm Guiver, Ramya Nataraj   +9 more
wiley   +1 more source

Donor–Recipient Epstein–Barr Virus Serostatus and Time‐Varying Risk of Posttransplant Lymphoproliferative Disorder in Kidney Transplant Recipients

Transplant Infectious Disease, EarlyView.
In a national US kidney transplant cohort, posttransplant lymphoproliferative disorder risk varied dynamically by donor–recipient Epstein–Barr virus serostatus. Donor‐positive/recipient‐negative recipients had the highest sustained risk, while donor‐negative/recipient‐negative recipients faced previously under‐recognized early risk, with PTLD strongly ...
Christie Rampersad, Seyed M. Hosseini‐Moghaddam, S. Joseph Kim   +2 more
wiley   +1 more source

Epstein-Barr Virus-Associated T/NK-Cell Neoplasms. [PDF]

J Med Virol
Sato Y, Okuno Y, Murata T, Kimura H.
europepmc   +1 more source

The Role of Belatacept‐Use and Senescence on Infectious and Mortality Complications After Kidney Transplantation

Transplant Infectious Disease, EarlyView.
ABSTRACT Introduction Studies evaluating the incidence of infections after belatacept as a substitute for calcineurin inhibitors (CNI) or antimetabolite in kidney transplant (KT) yielded conflicting results. We compared infectious outcomes after belatacept‐use to no belatacept‐use in KT recipients.
Hareesh Singam, Abdinoor Abdi, Wyatt Tarter, Ben Langworthy, Adam Bregman, Karam M. Obeid   +5 more
wiley   +1 more source

Epstein-Barr virus infection in children with liver transplantation. [PDF]

World J Hepatol
Onpoaree N, Leelakanok N, Sanpavat A, Sintusek P.   +3 more
europepmc   +1 more source

Lingual Dyskinesia as the Presenting Feature of Acquired Demyelinating Syndrome: A Case Report and Review of Differential Diagnoses

Journal of Paediatrics and Child Health, EarlyView.
Briana Davis, Ahmed Kaki, Eppie M. Yiu, Emma Macdonald‐Laurs   +3 more
wiley   +1 more source

Role of BK Virus CTLs in the Treatment of BK Virus–Associated Nephropathy in Kidney‐Transplant and Hematopoietic Cell Transplant Recipients

Transplant Infectious Disease, EarlyView.
Third‐party, BK virus‐specific cytotoxic T lymphocytes (CTLs) were safe and effective in reducing viremia in kidney and stem cell transplant recipients with BK virus nephropathy. However, they did not improve kidney function. Earlier administration may be more beneficial before nephropathy and irreversible damage occur.
Amanda Olson, Ye Ethan Li, Rafet Basar, Pinaki Banerjee, Indresh Kaur, Glorette Abueg, Melihate Sylejmani, Nadima Uprety, Rejeena Shrestha, Francia Reyes Silva, Valda Page, Richard E. Champlin, Dimitrios P. Kontoyiannis, Roy F. Chemaly, Elizabeth J. Shpall, Linda Moore, Osama A. Gaber, Katayoun Rezvani, Ala Abudayyeh   +18 more
wiley   +1 more source

Intrathecal rituximab for the treatment of Epstein-Barr virus-associated encephalitis. [PDF]

Front Immunol
Chapuis AG, Orozco JJ, Milano F.
europepmc   +1 more source

HHV‐8/KSHV in Solid Organ Transplantation: Current Gaps of Knowledge and Future Directions

Transplant Infectious Disease, EarlyView.
Risk mitigation strategies, including donors/recipients screening, DNAemia monitoring in recipients at risk, CNI‐to‐mTOR inhibitors switch, antivirals, and rituximab for KICS, may mitigate the impact of HHV‐8/KSHV infection in SOT. This review provides an update on KICS, identifies research gaps, and summarizes advances in screening and management ...
Alessandra Mularoni, Andrea Cona, Malgorzata Mikulska, Francesca Pecoraro, Carlotta Piazza, Elda De Vita, Giada Pietrosi, Matteo Bulati, Tiziana Lazzarotto, Mario Luppi   +9 more
wiley   +1 more source